Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/27/2853148/0/en/Renexxion-Ireland-Ltd-and-Dr-Falk-Pharma-GmbH-Announce-FDA-Clearance-of-the-Investigational-New-Drug-Application-for-Naronapride-to-Treat-Gastroparesis-and-Subsequent-Expansion-of-.html
https://www.globenewswire.com//news-release/2024/02/07/2825114/0/en/Renexxion-Ireland-s-European-Partner-Dr-Falk-Pharma-GmbH-has-Elected-PPI-non-responsive-Symptomatic-GERD-as-the-Second-Naronapride-Indication-to-Develop-and-Commercialize-in-their-.html
https://www.globenewswire.com//news-release/2024/02/01/2822007/0/en/Renexxion-to-Present-at-the-Oppenheimer-34%E1%B5%97%CA%B0-Annual-Healthcare-Life-Sciences-Conference.html
https://www.globenewswire.com//news-release/2024/01/24/2815101/0/en/Renexxion-Ireland-Ltd-Announces-FDA-Clearance-of-Investigational-New-Drug-IND-Application-for-Naronapride-to-Treat-PPI-Non-Responsive-Symptomatic-GERD.html
https://www.globenewswire.com//news-release/2023/12/20/2799647/0/en/Renexxion-Ireland-has-Completed-a-Successful-Pre-IND-Consultation-with-the-United-States-FDA-for-Development-of-Naronapride-for-Patients-with-PPI-non-responsive-Symptomatic-GERD.html
https://www.globenewswire.com//news-release/2023/11/30/2788459/0/en/Renexxion-Ireland-Announces-Issuance-of-Two-U-S-Patents-Covering-a-Novel-Crystal-Isoform-of-Naronapride.html
https://www.globenewswire.com//news-release/2023/10/04/2754437/0/en/Renexxion-to-Present-at-the-Oppenheimer-Healthcare-Private-Company-Showcase.html
https://www.clinicaltrialsarena.com/news/renexxion-ireland-gastroparesis-therapy/
https://www.clinicaltrialsarena.com/news/renexxion-cystic-fibrosis-preview/
https://www.prnewswire.com/news-releases/renexxion-announces-opening-of-investigational-new-drug-ind-application-for-naronapride-for-the-treatment-of-gastrointestinal-dysmotility-in-cystic-fibrosis-patients-301715995.html